Evidence for shared genetic risk factors between lymphangioleiomyomatosis and pulmonary function
ERJ Open Res. 2022 Jan 24;8(1):00375-2021. doi: 10.1183/23120541.00375-2021.…
Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data
Breast. 2022 Apr;62:1-9. doi: 10.1016/j.breast.2022.01.007. Epub…
Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin
Pharmaceuticals (Basel). 2021 Dec 24;15(1):19. doi: 10.3390/ph15010019.ABSTRACTCOVID-19…
CDK5RAP3, a New BRCA2 Partner That Regulates DNA Repair, Is Associated with Breast Cancer Survival
Cancers (Basel). 2022 Jan 12;14(2):353. doi: 10.3390/cancers14020353.ABSTRACTBRCA2…
Validation of Anticorrelated TGFβ Signaling and Alternative End-Joining DNA Repair Signatures that Predict Response to Genotoxic Cancer Therapy
Clin Cancer Res. 2022 Apr 1;28(7):1372-1382. doi: 10.1158/1078-0432.CCR-21-2846.ABSTRACTPURPOSE:…
Tcf1 is essential for initiation of oncogenic Notch1-driven chromatin topology in T-ALL
Blood. 2022 Apr 21;139(16):2483-2498. doi: 10.1182/blood.2021012077.ABSTRACTNOTCH1…
Sensory Features Introduced by Brewery Spent Grain with Impact on Consumers’ Motivations and Emotions for Fibre-Enriched Products
Foods. 2021 Dec 24;11(1):36. doi: 10.3390/foods11010036.ABSTRACTThe…
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
Nat Med. 2022 Jan;28(1):144-153. doi: 10.1038/s41591-021-01600-6.…
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia
N Engl J Med. 2022 Jan 6;386(1):11-23. doi: 10.1056/NEJMoa2109965.ABSTRACTBACKGROUND:…
Hodgkin Lymphoma: Recent Progress in Overall Management
In: Gallamini A, Juweid M, editors. Lymphoma [Internet]. Brisbane…
Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19
Blood Adv. 2022 Jan 8;6(3):848-853. doi: 10.1182/bloodadvances.2021006326.NO…
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
N Engl J Med. 2022 Feb 17;386(7):629-639. doi: 10.1056/NEJMoa2116596.…
